Arcus Biosciences (RCUS) Net Income towards Common Stockholders Growth (1y) (2018 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | -58.11% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -95.76% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -290.15% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 59.59% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -129.68% |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | -10.08% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 1,228.66% |
| 10 | Arcus Biosciences | 3.18 Bn | 2.36 Bn | - | -14.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -14.29% |
| Dec 31, 2025 | -12.77% |
| Sep 30, 2025 | -46.74% |
| Mar 31, 2025 | -2,700.00% |
| Dec 31, 2024 | -16.05% |
| Sep 30, 2024 | -29.58% |
| Jun 30, 2024 | -24.00% |
| Mar 31, 2024 | 95.00% |
| Dec 31, 2023 | -20.90% |
| Sep 30, 2023 | -9.23% |
| Jun 30, 2023 | -11.94% |
| Mar 31, 2023 | -17.65% |
| Dec 31, 2022 | -123.97% |
| Sep 30, 2022 | 16.64% |
| Jun 30, 2022 | 11.81% |
| Mar 31, 2022 | 6.33% |
| Dec 31, 2021 | 637.62% |
| Sep 30, 2021 | -4,379.64% |
| Jun 30, 2021 | -68.55% |
| Mar 31, 2021 | -161.57% |
| Dec 31, 2020 | -213.26% |
| Sep 30, 2020 | 108.28% |
| Jun 30, 2020 | -62.85% |
| Mar 31, 2020 | -60.99% |
| Dec 31, 2019 | -38.64% |
| Sep 30, 2019 | -106.99% |
| Jun 30, 2019 | -89.43% |
| Mar 31, 2019 | -35.44% |
| Dec 31, 2018 | 10.28% |
| Sep 30, 2018 | 54.07% |
| Jun 30, 2018 | -51.19% |
| Mar 31, 2018 | -74.36% |